| Literature DB >> 30379870 |
Laure-Amélie de Monteynard1, Sophie Matheron2,3, Sophie Grabar1,4,5, Pierre de Truchis6, Jacques Gilquin7, Juliette Pavie8, Odile Launay4,9, Jean-Luc Meynard10, Marie-Aude Khuong-Josses11, David Rey12, Aba Mahamat13, Rosemarie Dray-Spira1, Anne Simon14, Dominique Costagliola1, Sophie Abgrall1,15.
Abstract
BACKGROUND: The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30379870 PMCID: PMC6209163 DOI: 10.1371/journal.pone.0205385
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the population at cART initiation according to geographic origin in heterosexual men and women (France, 2006–2011, n = 4930).
| Heterosexual men (n = 2334) | Heterosexual women (n = 2596) | |||||||
|---|---|---|---|---|---|---|---|---|
| France | SSA | NFW | France | SSA | NFW | |||
| N = 1379 | N = 838 | N = 117 | P | N = 1347 | N = 1131 | N = 118 | P | |
| 43.7 (36.2–51.6) | 40.3 (34.5–47.1) | 45.4 (37.9–52.0) | <0.0001 | 38.6 (31.1–47.7) | 34.3 (29.4–40.3) | 42.1 (34.4–49.1) | <0.0001 | |
| 2006–2007 | 553 (40.1) | 338 (40.3) | 77 (65.8) | 511 (37.9) | 465 (41.1) | 73 (61.9) | ||
| 2008–2011 | 826 (59.9) | 500 (59.7) | 40 (34.2) | <0.0001 | 836 (62.1) | 666 (58.9) | 45 (38.1) | <0.0001 |
| Paris area | 584 (42.4) | 650 (77.6) | 45 (38.4) | 660 (49.0) | 826 (73.0) | 45 (38.1) | ||
| Southeast France | 162 (11.7) | 27 (3.2) | 0 (0) | 166 (12.3) | 32 (2.8) | 0 (0) | ||
| Other/Reunion island | 509 (36.9) | 161 (19.2) | 3 (2.6) | 448 (33.3) | 269 (23.8) | 1 (0.9) | ||
| French West Indies | 124 (9.0) | 0 (0) | 69 (59.0) | <0.0001 | 73 (5.4) | 4 (0.4) | 72 (61.0) | <0.0001 |
| <200 | 523 (37.9) | 348 (41.5) | 55 (47.0) | 412 (30.6) | 399 (35.3) | 47 (39.8) | ||
| ≥200–349 | 527 (38.2) | 331 (39.5) | 43 (36.7) | 578 (42.9) | 488 (43.2) | 53 (44.9) | ||
| ≥350–499 | 222 (16.1) | 121 (14.4) | 11 (9.4) | 251 (18.6) | 178 (15.7) | 12 (10.2) | ||
| ≥500 | 107 (7.8) | 38 (4.5) | 8 (6.8) | 0.0159 | 106 (7.9) | 66 (5.8) | 6 (5.1) | 0.0108 |
| 250 (122–342) | 231 (120–321) | 214 (56–299) | 0.0008 | 270 (171–357) | 251 (154–333) | 235 (148–313) | 0.0004 | |
| 4.88 (4.30–5.35) | 4.84 (4.26–5.34) | 4.92 (4.30–5.39) | 0.7363 | 4.57 (3.88–5.10) | 4.58 (3.91–5.11) | 4.64 (3.99–5.10) | 0.8677 | |
| 230 (16.7) | 164 (19.6) | 34 (33.3) | <0.0001 | 166 (12.3) | 171 (15.1) | 22 (18.6) | 0.0400 | |
| 53 (3.8) | 89 (10.6) | 4 (3.4) | <0.0001 | 34 (2.5) | 75 (6.6) | 4 (3.4) | <0.0001 | |
| 36 (2.6) | 20 (2.4) | 3 (2.6) | 0.9480 | 48 (3.6) | 38 (3.4) | 0 (0) | 0.1156 | |
| Never | 281 (20.4) | 375 (44.7) | 63 (53.8) | 337 (25.0) | 701 (62.0) | 61 (51.7) | ||
| Previous | 151 (10.9) | 75 (9.0) | 7 (6.0) | 56 (4.2) | 27 (2.4) | 3 (2.5) | ||
| Current | 411 (29.8) | 175 (20.9) | 14 (12.0) | 221 (16.4) | 69 (6.1) | 8 (6.8) | ||
| Unknown | 536 (38.9) | 213 (25.4) | 33 (28.2) | <0.0001 | 733 (54.4) | 334 (29.5) | 46 (39.0) | <0.0001 |
| <18 | 11 (0.8) | 15 (1.8) | 0 (0) | 49 (6.6) | 19 (1.7) | 3 (2.5) | ||
| ≥18–30 | 1024 (74.3) | 653 (77.9) | 59 (50.4) | 911 (67.6) | 835 (73.8) | 51 (43.2) | ||
| >30 | 69 (5.0) | 70 (8.4) | 4 (3.4) | 140 (10.4) | 120 (10.6) | 4 (3.4) | ||
| Unknown | 275 (19.9) | 100 (11.9) | 54 (46.2) | <0.0001 | 247 (18.3) | 157 (13.9) | 60 (50.9) | <0.0001 |
| 2.6 (1.4–4.0) | 2.6 (1.4–4.1) | 2.3 (1.9–3.6) | 0.1636 | 2.6 (1.5–4.0) | 2.7 (1.6–4.1) | 1.8 (1.0–3.5) | <0.0001 | |
Data are counts (proportions) and median (interquartile range)
Including French West Indies (Martinique, Guadeloupe, French Guyana)
The Chi2 and Kruskal-Wallis tests were used to compare the demographic, immunovirological and clinical characteristics of the individuals
Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral
Crude and adjusted incidence rates (IRs) per 1000 person-years (PY) and 95% confidence intervals (95% CI)), and crude and adjusted rate ratios (RRs) and 95% CI of clinical events/deaths by geographic origin, in heterosexual men and women (Poisson regression, n = 4930, France, 2006–2012).
| Heterosexual men (n = 2334) | Heterosexual women (n = 2596) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical events | Geographic | People | Events | Crude | Adjusted | Crude | Adjusted | People | Events | Crude | Adjusted | Crude | Adjusted |
| origin | with | IRs per 1000 PY | IRs per 1000 PY | RRs (95%CI) | RRs (95%CI) | with | IRs per 1000 PY | IRs per 1000 PY | RRs (95%CI) | RRs (95%CI) | |||
| event(s) | p-value | p-value | event(s) | p-value | p-value | ||||||||
| France | 71 | 87 | 22.4 | 26.3 | 1 | 1 | 43 | 51 | 13.6 | 10.3 | 1 | 1 | |
| SSA | 49 | 54 | 22.9 | 34.0 | 1.02 (0.73–1.43) | 1.29 (0.86–1.94) | 47 | 55 | 16.7 | 11.8 | 1.23 (0.84–1.80) | 1.15 (0.75–1.77) | |
| NFW | 8 | 11 | 37.4 | 23.6 | 1.67 (0.89–3.12) | 0.90 (0.44–1.82) | 5 | 5 | 18.5 | 20.4 | 1.36 (0.54–3.42) | 1.97 (0.70–5.60) | |
| 0.3246 | 0.4168 | 0.5180 | 0.4450 | ||||||||||
| France | 19 | 19 | 4.9 | 5.3 | 1 | 1 | 8 | 8 | 2.1 | 3.5 | 1 | 1 | |
| SSA | 14 | 14 | 5.9 | 9.5 | 1.21 (0.61–2.42) | 1.78 (0.79–4.01) | 11 | 11 | 3.3 | 8.0 | 1.57 (0.63–3.90) | 2.31 (0.81–6.61) | |
| NFW | 1 | 1 | 3.4 | 3.0 | 0.69 (0.09–5.18) | 0.56 (0.06–4.98) | 0 | 0 | |||||
| 0.7724 | 0.2896 | 0.3051 | 0.1291 | ||||||||||
| France | 71 | 77 | 19.9 | 29.1 | 1 | 1 | 55 | 59 | 15.7 | 31.6 | 1 | 1 | |
| SSA | 53 | 62 | 26.3 | 45.4 | 1.33 (0.95–1.85) | 1.56 (1.07–2.29) | 36 | 41 | 12.4 | 34.5 | 0.79 (0.53–1.18) | 1.09 (0.70–1.71) | |
| NFW | 10 | 10 | 34.0 | 49.5 | 1.71 (0.89–3.31) | 1.70 (0.82–3.56) | 6 | 6 | 22.2 | 50.6 | 1.41 (0.61–3.28) | 1.60 (0.58–4.39) | |
| 0.1253 | 0.0477 | 0.3102 | 0.6502 | ||||||||||
| France | 38 | 39 | 10.0 | 16.4 | 1 | 1 | 29 | 29 | 7.7 | 4.7 | 1 | 1 | |
| SSA | 31 | 31 | 13.2 | 26.0 | 1.31 (0.82–2.10) | 1.59 (0.93–2.72) | 32 | 35 | 10.6 | 9.0 | 1.37 (0.84–2.25) | 2.04 (1.18–3.53) | |
| NFW | 3 | 3 | 10.2 | 12.6 | 1.01 (0.31–3.28) | 0.77 (0.21–2.83) | 6 | 6 | 22.2 | 36.0 | 2.88 (1.19–6.93) | 7.87 (2.54–24.4) | |
| 0.5332 | 0.1957 | 0.0790 | 0.0010 | ||||||||||
| France | 36 | 42 | 10.8 | 7.3 | 1 | 1 | 25 | 27 | 7.2 | 11.9 | 1 | 1 | |
| SSA | 19 | 20 | 8.5 | 7.9 | 0.78 (0.46–1.33) | 1.08 (0.59–1.95) | 10 | 10 | 3.0 | 5.8 | 0.42 (0.20–0.87) | 0.49 (0.21–1.13) | |
| NFW | 3 | 3 | 10.2 | 11.4 | 0.94 (0.29–3.04) | 1.56 (0.44–5.55) | 0 | 0 | |||||
| 0.6608 | 0.8016 | 0.0121 | 0.0240 | ||||||||||
| France | 27 | 30 | 1.8 | 1.4 | 1 | 1 | 24 | 25 | 4.3 | 7.8 | 1 | 1 | |
| SSA | 8 | 8 | 0.4 | 0.6 | 0.24 (0.03–1.91) | 0.40 (0.04–3.60) | 17 | 19 | 1.8 | 3.6 | 0.43 (0.17–1.09) | 0.45 (0.16–1.31) | |
| NFW | 2 | 2 | 3.4 | 4.6 | 1.88 (0.23–15.30) | 3.30 (0.23–47.90) | 4 | 4 | 7.4 | 8.8 | 1.74 (0.40–7.56) | 1.12 (0.20–6.31) | |
| 0.1997 | 0.4395 | 0.1006 | 0.3042 | ||||||||||
| France | 33 | 36 | 9.3 | 10.9 | 1 | 1 | 21 | 24 | 6.4 | 8.7 | 1 | 1 | |
| SSA | 9 | 12 | 5.1 | 8.8 | 0.55 (0.29–1.05) | 0.80 (0.38–1.67) | 9 | 9 | 2.7 | 5.9 | 0.43 (0.20–0.92) | 0.68 (0.29–1.58) | |
| NFW | 1 | 2 | 6.8 | 7.6 | 0.73 (0.18–3.04) | 0.70 (0.15–3.11) | 0 | 0 | |||||
| 0.1669 | 0.7589 | 0.0208 | 0.1932 | ||||||||||
| France | 20 | 21 | 5.4 | 9.6 | 1 | 1 | 24 | 26 | 6.9 | 7.4 | 1 | 1 | |
| SSA | 9 | 9 | 3.8 | 7.7 | 0.71 (0.32–1.54) | 0.80 (0.32–2.00) | 17 | 17 | 5.2 | 6.3 | 0.74 (0.40–1.37) | 0.85 (0.43–1.71) | |
| NFW | 1 | 1 | 3.4 | 3.7 | 0.63 (0.08–4.66) | 0.38 (0.05–3.28) | 1 | 1 | 3.7 | 5.8 | 0.53 (0.07–3.94) | 0.78 (0.09–6.83) | |
| 0.6274 | 0.5875 | 0.5504 | 0.8923 | ||||||||||
Abbreviations: SSA, Sub-Saharan Africa; NFW, Non-French West-Indies; cART, combination antiretroviral therapy
Adjusted for variables at cART initiation: age, the region of care, the CD4 cell count, the pVL, pre-existing AIDS status, hepatitis B virus antigen and/or anti-hepatitis C virus antibody status, and the smoking status for all analyses, plus the body mass index for cardiovascular diseases